EGFR and non-small cell lung carcinoma: Therefore, we performed this pooled analysis of randomized clinical trials to assess the efficacy and tolerability of adding pemetrexed-based chemotherapy to gefitinib as the first-line treatment for advanced patients with EGFR-mutant NSCLC.